Efficacy of Reslizumab for the Treatment of Chronic Rhinosinusitis A Double Blind, Randomized, Placebo-controlled, Phase III Trial
Latest Information Update: 07 Jan 2020
At a glance
- Drugs Reslizumab (Primary)
- Indications Rhinosinusitis
- Focus Therapeutic Use
- 30 Jan 2018 Planned End Date changed from 1 Jul 2017 to 1 Jul 2019.
- 30 Jan 2018 Planned primary completion date changed from 1 Jul 2017 to 1 Jul 2019.
- 20 Jun 2016 New trial record